Enterprise Value
16.8B
Cash
3.523B
Avg Qtr Burn
-434.4M
Short % of Float
2.86%
Insider Ownership
19.64%
Institutional Own.
50.09%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BRUKINSA (zanubrutinib) Details Blood cancer, Cancer, Small lymphocytic lymphoma , Chronic lymphocytic leukemia | Approved Quarterly sales | |
TEVIMBRA Details Cancer, Esophageal Squamous Cell Carcinoma | PDUFA Approval decision | |
BRUKINSA + obinutuzumab Details Cancer, Follicular lymphoma | PDUFA Approval decision | |
Tislelizumab+ fluoropyrimidine + platinum chemotherapy Details Cancer, Gastroesophageal junction tumors, Gastroesophageal adenocarcinomas | BLA Submission | |
BRUKINSA + tislelizumab Details Cancer, Hepatocellular carcinoma | Phase 3 Data readout | |
Tislelizumab Details Cancer, Non-small cell lung carcinoma | Phase 3 Data readout | |
Ociperlimab (Anti-TIGIT) Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
BGB-11417 (Bcl-2 inhibitor) Details Waldenstrom macroglobulinemia, Chronic lymphocytic leukemia | Phase 3 Initiation | |
Ociperlimab (anti-TIGIT Ab) + tislelizumab Details Non-small cell lung carcinoma, Small cell lung cancer, Cervical cancer, Esophageal Squamous Cell Carcinoma | Phase 2 Data readout | |
BGB-16673 (BTK CDAC) Details Cancer, B-cell malignancies | Phase 1 Data readout | |
BGB-A445 w/ tislelizumab Details Renal cell carcinoma, Cancer, Bladder cancer, Melanoma | Phase 1 Update |